New oral drugs for multiple sclerosis

被引：20
|
作者：
Gasperini, Claudio [1 ,2 ]
Ruggieri, S. [2 ]
机构：
[1] Azienda Osped S Camillo Forlanini, Dipartimento Testa Collo, I-00152 Rome, Italy
[2] Azienda Osped S Camillo Forlanini, Ctr Sclerosi Multipla, I-00152 Rome, Italy
来源：
NEUROLOGICAL SCIENCES | 2009年 / 30卷
关键词：
Multiple sclerosis; Oral treatment; Fingolimod; Fumaric acid; Cladribine; Teriflunomide; Laquinimod; SPHINGOSINE; 1-PHOSPHATE; PROGRESSIVE MS; CLADRIBINE; FTY720;
D O I：
10.1007/s10072-009-0146-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Disease-modifying treatments are now available in relapsing-remitting and secondary progressive multiple sclerosis (MS), and their beneficial effects have been shown in several clinical studies. However, as these treatments are only partially effective in halting the MS disease process and are frequently associated with side effects and suboptimal patient adherence, new oral therapeutic approaches are warranted. This review focuses on advances in current and novel oral treatment approaches for MS. Several pivotal reports have provided promising results for new oral therapies evaluating the safety and efficacy of new agents including fingolimod, fumaric acid, cladribine, teriflunomide and laquinimod.
引用
收藏
页码：179 / 183
页数：5
相关论文
共 50 条
  • [1] New oral drugs for multiple sclerosis
    Claudio Gasperini
    S. Ruggieri
    Neurological Sciences, 2009, 30 : 179 - 183
  • [2] New oral drugs for the treatment of multiple sclerosis
    Chard, Declan
    Trip, Anand
    Chataway, Jeremy
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (09) : 502 - 503
  • [3] New challenges in multiple sclerosis: are oral drugs translatable into the clinic?
    Gasperini, Claudio
    Ruggieri, Serena
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2012, 2 (04) : 339 - 342
  • [4] New oral drugs show promise for the treatment of multiple sclerosis
    不详
    FUTURE MEDICINAL CHEMISTRY, 2010, 2 (03) : 308 - 308
  • [5] Emerging oral drugs for multiple sclerosis
    Gasperini, Claudio
    Cefaro, Luca Ausili
    Borriello, Giovanna
    Tosto, Giuseppe
    Prosperini, Luca
    Pozzilli, Carlo
    EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (03) : 465 - 477
  • [6] Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis
    di Nuzzo, Luigi
    Orlando, Rosamaria
    Nasca, Carla
    Nicoletti, Ferdinando
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 555 - 567
  • [7] New drugs for the treatment of multiple sclerosis
    Rio, Jordi
    REVISTA DE NEUROLOGIA, 2018, 66 (08) : 253 - 253
  • [8] Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
    Jadidi-Niaragh, Farhad
    Mirshafiey, Abbas
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2011, 5 (01) : 66 - 80
  • [9] Usage trend of oral drugs for multiple sclerosis in argentina
    Alonso, R.
    Silva, B.
    Eizaguirre, M. B.
    Man, F.
    Lopez Bisso, A.
    Cohen, L.
    Pita, C.
    Rojas, J.
    Patrucco, L.
    Cristiano, E.
    Tkachuk, V.
    Balbuena, M. E.
    Contentti, E. Carnero
    Lopez, P.
    Pettinicchi, J.
    Deri, N.
    Miguez, J.
    Pappolla, A.
    Fernandez Liguori, N.
    Correale, J.
    Carra, A.
    Garcea, O.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 560 - 560
  • [10] Skin adverse events occurring during treatment with new oral drugs for multiple sclerosis
    Ruiz Pena, J. L.
    Navarro Mascarell, G.
    Paramo Camino, M. D.
    Perez, S.
    Eichau, S.
    Pacheco, E.
    Damas, F.
    Izquierdo Ayuso, G.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 557 - 557
12345